{"id":"physician-s-choice-soc","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin photosensitivity"},{"rate":null,"effect":"Local tissue irritation at treatment site"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a scintillator-based photodynamic therapy (PDT) approach developed by Rakuten Medical that combines a photosensitizing agent with X-ray activation. Upon X-ray exposure, the agent emits light that activates the photosensitizer to produce singlet oxygen and reactive oxygen species, inducing localized tumor cell death. This mechanism allows deep tissue penetration compared to traditional light-based PDT.","oneSentence":"Physician's Choice SOC is an X-ray activated photodynamic therapy agent that generates reactive oxygen species upon X-ray irradiation to destroy cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:26:15.076Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT06875128","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease","status":"RECRUITING","sponsor":"Delcath Systems Inc.","startDate":"2026-01-29","conditions":"Metastatic Breast Cancer in the Liver","enrollment":90},{"nctId":"NCT05849298","phase":"PHASE2","title":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-03","conditions":"Prostatic Neoplasm","enrollment":49},{"nctId":"NCT06203210","phase":"PHASE3","title":"A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-05-21","conditions":"Small Cell Lung Cancer","enrollment":540},{"nctId":"NCT07251062","phase":"PHASE2, PHASE3","title":"A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-12-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":737},{"nctId":"NCT06699212","phase":"PHASE3","title":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases","status":"RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2024-12-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":412},{"nctId":"NCT04644289","phase":"PHASE2","title":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","status":"RECRUITING","sponsor":"AGO Research GmbH","startDate":"2022-05-05","conditions":"Epithelial Ovarian Cancer","enrollment":60},{"nctId":"NCT06905509","phase":"PHASE2","title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2025-07-31","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","enrollment":25},{"nctId":"NCT04527991","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2021-01-13","conditions":"Locally Advanced or Metastatic Unresectable Urothelial Cancer","enrollment":712},{"nctId":"NCT06643585","phase":"PHASE3","title":"A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse","status":"RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2025-04-22","conditions":"Breast Cancer","enrollment":180},{"nctId":"NCT03769506","phase":"PHASE3","title":"ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2019-05-09","conditions":"Head and Neck Cancer","enrollment":135},{"nctId":"NCT05255107","phase":"PHASE2, PHASE3","title":"Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers","status":"UNKNOWN","sponsor":"Peschke GmbH","startDate":"2022-03-14","conditions":"Keratitis, Corneal Ulcer","enrollment":468},{"nctId":"NCT04676243","phase":"PHASE3","title":"Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML","status":"WITHDRAWN","sponsor":"University Hospital Heidelberg","startDate":"2022-05","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT01802970","phase":"PHASE1","title":"Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2012-12","conditions":"Metastatic Breast Cancer","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Physician's Choice SOC","genericName":"Physician's Choice SOC","companyName":"Rakuten Medical, Inc.","companyId":"rakuten-medical-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Physician's Choice SOC is an X-ray activated photodynamic therapy agent that generates reactive oxygen species upon X-ray irradiation to destroy cancer cells. Used for Locally advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}